Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 19-Nov-24 8:40 PM View:  | Schneyer Mark C. EVP, Chief Financial Officer | Acadia Pharmaceuticals Inc. (ACAD) | 19-Nov-24 | Planned Option Sale | 10,259 | $16.81 | $172,454.00 | (16%) 63.56K to 53.3K | |
| 19-Nov-24 8:41 PM View: | Kihara James Principal Accounting Officer | Acadia Pharmaceuticals Inc. (ACAD) | 19-Nov-24 | Planned Option Sale | 4,073 | $16.81 | $68,467.10 | (17%) 23.94K to 19.86K | |
| 19-Nov-24 8:43 PM View: | Teehan Brendan EVP, COO, Head of Commercial | Acadia Pharmaceuticals Inc. (ACAD) | 19-Nov-24 | Planned Option Sale | 10,329 | $16.81 | $173,630.00 | (14%) 72.43K to 62.1K | |
| 19-Nov-24 8:40 PM View: | Schneyer Mark C. EVP, Chief Financial Officer | Acadia Pharmaceuticals Inc. (ACAD) | 17-Nov-24 | Option Exercise | 19,826 | -- | -- | 45% 43.73K to 63.56K | |
| 19-Nov-24 8:41 PM View: | Kihara James Principal Accounting Officer | Acadia Pharmaceuticals Inc. (ACAD) | 17-Nov-24 | Option Exercise | 7,930 | -- | -- | 50% 16.01K to 23.94K | |
| 19-Nov-24 8:43 PM View: | Teehan Brendan EVP, COO, Head of Commercial | Acadia Pharmaceuticals Inc. (ACAD) | 17-Nov-24 | Option Exercise | 19,826 | -- | -- | 38% 52.61K to 72.43K | |
| 15-Oct-24 6:05 PM View: | Ndu Adora Director | Acadia Pharmaceuticals Inc. (ACAD) | 12-Oct-24 | Option Exercise | 4,381 | -- | -- | 40% 11.03K to 15.41K | |
| 20-Aug-24 6:46 PM View: | Schneyer Mark C. EVP, Chief Financial Officer | Acadia Pharmaceuticals Inc. (ACAD) | 19-Aug-24 | Sale (Planned) | 9,733 | $15.28 | $148,720.00 | (18%) 53.47K to 43.73K | |
| 20-Aug-24 6:43 PM View: | Teehan Brendan EVP, COO, Head of Commercial | Acadia Pharmaceuticals Inc. (ACAD) | 19-Aug-24 | Sale (Planned) | 9,534 | $15.28 | $145,680.00 | (15%) 61.71K to 52.18K | |
| 20-Aug-24 6:40 PM View: | Davis Stephen CEO Director | Acadia Pharmaceuticals Inc. (ACAD) | 19-Aug-24 | Sale (Planned) | 31,747 | $15.28 | $485,094.00 | (15%) 218.3K to 186.56K | |
| 20-Aug-24 6:46 PM View: | Schneyer Mark C. EVP, Chief Financial Officer | Acadia Pharmaceuticals Inc. (ACAD) | 16-Aug-24 | Grant | 18,904 | -- | -- | 55% 34.56K to 53.47K | |
| 20-Aug-24 6:43 PM View: | Teehan Brendan EVP, COO, Head of Commercial | Acadia Pharmaceuticals Inc. (ACAD) | 16-Aug-24 | Grant | 18,653 | -- | -- | 43% 43.06K to 61.71K | |
| 20-Aug-24 6:40 PM View: | Davis Stephen CEO Director | Acadia Pharmaceuticals Inc. (ACAD) | 16-Aug-24 | Grant | 62,115 | -- | -- | 40% 156.19K to 218.3K | |
| 11-Jun-24 6:00 PM View: | Schneyer Mark C. EVP, Chief Financial Officer | Acadia Pharmaceuticals Inc. (ACAD) | 10-Jun-24 | Planned Option Sale | 975 | $14.79 | $14,420.20 | (3%) 35.54K to 34.56K | |
| 11-Jun-24 6:00 PM View: | Schneyer Mark C. EVP, Chief Financial Officer | Acadia Pharmaceuticals Inc. (ACAD) | 08-Jun-24 | Option Exercise | 1,893 | -- | -- | 6% 33.65K to 35.54K | |
| 31-May-24 6:00 PM View: | Brege Laura Director | Acadia Pharmaceuticals Inc. (ACAD) | 29-May-24 | Option Exercise | 6,652 | -- | -- | 49% 13.5K to 20.15K | |
| 31-May-24 6:00 PM View: | Ndu Adora Director | Acadia Pharmaceuticals Inc. (ACAD) | 29-May-24 | Option Exercise | 6,652 | -- | -- | 152% 4.38K to 11.03K | |
| 31-May-24 6:00 PM View: | Harrigan Edmund Director | Acadia Pharmaceuticals Inc. (ACAD) | 29-May-24 | Option Exercise | 6,652 | -- | -- | 35% 19.0K to 25.65K | |
| 31-May-24 6:00 PM View: | Daly James M Director | Acadia Pharmaceuticals Inc. (ACAD) | 29-May-24 | Option Exercise | 6,652 | -- | -- | 37% 18.0K to 24.65K | |
| 31-May-24 6:00 PM View: | Soland Daniel B Director | Acadia Pharmaceuticals Inc. (ACAD) | 29-May-24 | Option Exercise | 6,652 | -- | -- | 24% 28.0K to 34.65K | |
| 31-May-24 6:00 PM View: | Garofalo Elizabeth A. Director | Acadia Pharmaceuticals Inc. (ACAD) | 29-May-24 | Option Exercise | 6,652 | -- | -- | 42% 15.86K to 22.51K | |
| 31-May-24 4:10 PM View: | Baker Bros Advisors LLC Director 10% Owner | Acadia Pharmaceuticals Inc. (ACAD) | 29-May-24 | Grant | 37,548 | -- | -- | < 1% 43.16M to 43.2M | |
| 03-May-24 6:00 PM View: | Kihara James Principal Accounting Officer | Acadia Pharmaceuticals Inc. (ACAD) | 02-May-24 | Planned Option Sale | 1,326 | $16.94 | $22,462.40 | (8%) 15.7K to 14.37K | |
| 03-May-24 6:00 PM View: | Teehan Brendan EVP, COO, Head of Commercial | Acadia Pharmaceuticals Inc. (ACAD) | 02-May-24 | Planned Option Sale | 3,477 | $16.94 | $58,900.40 | (8%) 45.61K to 42.13K | |
| 03-May-24 6:00 PM View: | Davis Stephen CEO Director | Acadia Pharmaceuticals Inc. (ACAD) | 02-May-24 | Planned Option Sale | 11,427 | $16.94 | $193,573.00 | (7%) 166.66K to 155.23K | |
| 03-May-24 6:00 PM View: | Schneyer Mark C. EVP, Chief Financial Officer | Acadia Pharmaceuticals Inc. (ACAD) | 02-May-24 | Planned Option Sale | 3,503 | $16.94 | $59,340.80 | (10%) 35.56K to 32.05K | |
| 03-May-24 6:00 PM View: | Kihara James Principal Accounting Officer | Acadia Pharmaceuticals Inc. (ACAD) | 01-May-24 | Option Exercise | 2,596 | -- | -- | 20% 13.1K to 15.7K | |
| 03-May-24 6:00 PM View: | Teehan Brendan EVP, COO, Head of Commercial | Acadia Pharmaceuticals Inc. (ACAD) | 01-May-24 | Option Exercise | 6,814 | -- | -- | 18% 38.8K to 45.61K | |
| 03-May-24 6:00 PM View: | Davis Stephen CEO Director | Acadia Pharmaceuticals Inc. (ACAD) | 01-May-24 | Option Exercise | 22,391 | -- | -- | 16% 144.27K to 166.66K | |
| 03-May-24 6:00 PM View: | Schneyer Mark C. EVP, Chief Financial Officer | Acadia Pharmaceuticals Inc. (ACAD) | 01-May-24 | Option Exercise | 6,814 | -- | -- | 24% 28.74K to 35.56K | |
| 09-Apr-24 6:00 PM View: | Teehan Brendan EVP, COO, Head of Commercial | Acadia Pharmaceuticals Inc. (ACAD) | 08-Apr-24 | Planned Option Sale | 2,568 | $17.87 | $45,890.20 | (6%) 41.36K to 38.8K | |
| 09-Apr-24 6:00 PM View: | Davis Stephen CEO Director | Acadia Pharmaceuticals Inc. (ACAD) | 08-Apr-24 | Planned Option Sale | 26,574 | $17.87 | $474,877.00 | (16%) 170.84K to 144.27K | |
| 09-Apr-24 6:00 PM View: | Schneyer Mark C. EVP, Chief Financial Officer | Acadia Pharmaceuticals Inc. (ACAD) | 08-Apr-24 | Planned Option Sale | 2,716 | $17.87 | $48,534.90 | (9%) 31.46K to 28.74K | |
| 09-Apr-24 6:00 PM View: | Kihara James Principal Accounting Officer | Acadia Pharmaceuticals Inc. (ACAD) | 08-Apr-24 | Planned Option Sale | 1,790 | $17.87 | $31,987.30 | (12%) 14.89K to 13.1K | |
| 09-Apr-24 6:00 PM View: | Kihara James Principal Accounting Officer | Acadia Pharmaceuticals Inc. (ACAD) | 07-Apr-24 | Option Exercise | 1,489 | -- | -- | 11% 13.4K to 14.89K | |
| 09-Apr-24 6:00 PM View: | Teehan Brendan EVP, COO, Head of Commercial | Acadia Pharmaceuticals Inc. (ACAD) | 05-Apr-24 | Option Exercise | 5,024 | -- | -- | 14% 36.34K to 41.36K | |
| 09-Apr-24 6:00 PM View: | Davis Stephen CEO Director | Acadia Pharmaceuticals Inc. (ACAD) | 05-Apr-24 | Option Exercise | 51,999 | -- | -- | 44% 118.84K to 170.84K | |
| 09-Apr-24 6:00 PM View: | Schneyer Mark C. EVP, Chief Financial Officer | Acadia Pharmaceuticals Inc. (ACAD) | 05-Apr-24 | Option Exercise | 5,275 | -- | -- | 20% 26.18K to 31.46K | |
| 09-Apr-24 6:00 PM View: | Kihara James Principal Accounting Officer | Acadia Pharmaceuticals Inc. (ACAD) | 05-Apr-24 | Option Exercise | 2,010 | -- | -- | 18% 11.39K to 13.4K | |
| 27-Mar-24 8:00 PM View: | Teehan Brendan EVP, COO, Head of Commercial | Acadia Pharmaceuticals Inc. (ACAD) | 27-Mar-24 | Sale (Planned) | 5,140 | $17.90 | $92,006.00 | (12%) 41.48K to 36.34K | |
| 27-Mar-24 7:58 PM View: | Davis Stephen CEO Director | Acadia Pharmaceuticals Inc. (ACAD) | 27-Mar-24 | Sale (Planned) | 17,714 | $17.90 | $317,081.00 | (13%) 136.56K to 118.84K | |
| 27-Mar-24 7:57 PM View: | Schneyer Mark C. EVP, Chief Financial Officer | Acadia Pharmaceuticals Inc. (ACAD) | 27-Mar-24 | Sale (Planned) | 5,434 | $17.90 | $97,268.60 | (17%) 31.62K to 26.18K | |
| 27-Mar-24 7:58 PM View: | Davis Stephen CEO Director | Acadia Pharmaceuticals Inc. (ACAD) | 25-Mar-24 | Grant | 34,666 | -- | -- | 34% 101.89K to 136.56K | |
| 27-Mar-24 7:57 PM View: | Schneyer Mark C. EVP, Chief Financial Officer | Acadia Pharmaceuticals Inc. (ACAD) | 25-Mar-24 | Grant | 10,550 | -- | -- | 50% 21.07K to 31.62K | |
| 27-Mar-24 8:00 PM View: | Teehan Brendan EVP, COO, Head of Commercial | Acadia Pharmaceuticals Inc. (ACAD) | 25-Mar-24 | Grant | 10,048 | -- | -- | 32% 31.43K to 41.48K | |
| 27-Feb-24 6:07 PM View: | Kihara James Principal Accounting Officer | Acadia Pharmaceuticals Inc. (ACAD) | 26-Feb-24 | Planned Option Sale | 474 | $24.67 | $11,693.60 | (4%) 11.87K to 11.39K | |
| 27-Feb-24 6:10 PM View: | Teehan Brendan EVP, COO, Head of Commercial | Acadia Pharmaceuticals Inc. (ACAD) | 26-Feb-24 | Planned Option Sale | 624 | $24.67 | $15,394.10 | (2%) 32.06K to 31.43K | |
| 27-Feb-24 6:02 PM View: | Davis Stephen CEO Director | Acadia Pharmaceuticals Inc. (ACAD) | 26-Feb-24 | Planned Option Sale | 5,577 | $24.67 | $137,585.00 | (5%) 107.47K to 101.89K | |
| 27-Feb-24 6:13 PM View: | Schneyer Mark C. EVP, Chief Financial Officer | Acadia Pharmaceuticals Inc. (ACAD) | 26-Feb-24 | Planned Option Sale | 772 | $24.67 | $19,045.20 | (4%) 21.84K to 21.07K | |
| 27-Feb-24 6:02 PM View: | Davis Stephen CEO Director | Acadia Pharmaceuticals Inc. (ACAD) | 23-Feb-24 | Option Exercise | 10,946 | -- | -- | 11% 96.52K to 107.47K |
